Apimeds Pharmaceuticals US, Inc.
APUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001894525
No open-market purchases or sales by Apimeds Pharmaceuticals US, Inc. insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $383.7K in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Apimeds Pharmaceuticals US, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 7 | 1 | 6 | 0 |
| Shares | 395.7K | 59.0K | 448.8K | +112.0K (+33.3%) |
| Value | $648.9K | $96.7K | $803.0K | +$250.8K (+45.4%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Apimeds Pharmaceuticals US, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 95,929 | $171.6K | 0.00% |
| Vanguard Fiduciary Trust Co | 24,039 | $43.0K | 0.00% |
| Two Sigma Securities, LLC | 10,550 | $18.9K | 0.00% |
Sold out (3)
Institutions that held Apimeds Pharmaceuticals US, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Jane Street Group, LLC | 27,188 | $44.6K |
| Bank of America Corp | 40 | $66 |
| Tower Research Capital LLC (TRC) | 10 | $16 |
Not filed for Q1 2026 yet (1)
Institutions that held Apimeds Pharmaceuticals US, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 58,992 | $96.7K |